Orthofix (NSDQ:OFIX) today said it entered an exclusive license agreement to commercialize Igea’s bone, cartilage and soft tissue stimulation products in the U.S. and Canada.
Through the agreement, Orthofix has the rights to pursue FDA approvals and commercialization of Italy-based Igea’s platform of orthopedic products. The products will also be marketed under the Orthofix brand and will expand the company’s bone growth therapies portfolio of pulsed electromagnetic field (PEMF) products with other indications for low-intensity pulsed ultrasound (LIPUS) and capacitive coupling (CC) for fracture management.
“Orthofix is the U.S. market leader with our PEMF technology bone growth stimulation systems indicated for post-operative spinal fusions and treating bone fractures that have not healed after surgery, and Igea is the European market and technology leader for bone and joint stimulation,” Orthofix president and CEO Jon Serbousek said in a news…